Clinical Trials Logo

Clinical Trial Summary

Inflammation can influence several biochemical measurements those commonly used to interpret micronutrient status in children. Our primary objective is to investigate the effects of inflammation on several biochemical measurements used to interpret micronutrient status in children. A total of 40 infants (9-18 mo of age) will participate in this study. Investigators will use PENTA vaccines as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)). The investigators will also use two different stable isotopic retinols for the assessment of total body vitamin A stores. Baseline blood samples (5 mL) will be obtained from all infants and then randomly selected 30 infants will receive PENTA vaccines, while the other 10 infants will receive no vaccines. 24 hours after vaccination a finger-prick blood sample will be obtained from the infants in the vaccinated group to measure CRP and on the same day, blood samples (5 mL) will be obtained from infants who develop inflammation (CRP> 5mg/L) in the vaccine group and also from infants in the control group. Thus estimated plasma micronutrients and vitamin A stores before and after inflammation will calculate the effects of inflammation on the interpretation of micronutrient deficiencies based on biochemical indicator assessment.


Clinical Trial Description

Background:

Subclinical micronutrient deficiencies remain a hidden aspect of malnutrition for which comprehensive data are lacking. Defining subclinical micronutrient deficiencies requires considering the prevalence of inflammation and its implications for the interpretation of micronutrient deficiencies based on biochemical indicator assessment. This study will provide a comprehensive profile of micronutrient status and antimicrobial resistance in a cohort of young children living in the densely populated urban slum.

Hypothesis:

I. Inflammation can influence several biochemical measurements those commonly used to interpret micronutrient status in children II. Micronutrient assessments can be performed successfully using finger/heel prick blood samples with microsamplers, thus increasing the ease of blood collection and reducing costs for cold storage and transport to the analytical laboratory.

Specific Objectives:

Our primary objective is to investigate the effects of inflammation on several biochemical measurements used to interpret micronutrient status in children. Our secondary aim is to test the applicability of a blood spot device allowing the determination of micronutrient status in field settings. Our exploratory objective is to make a comparative analysis of gut antimicrobial resistance genes (AMR) and resistome profile in children.

Methods:

A total of 40 infants (9-18 mo of age) will participate in this study. In this study, investigators will use two different stable isotopic vitamin A e.g., 13C10-retinyl acetate and 13C4-retinyl acetate. 400 μg of these isotopes, dissolved in 0.5 mL of sunflower oil, will be provided directly into the infant's mouth by using a direct replacement pipette. Mothers will be asked to breastfeed their infant after oral dosing to enhance absorption of the labeled vitamin A. Specific activity of 13C10- and 13C4- retinyl acetate in the blood samples will be measured by liquid chromatography-tandem mass spectrometry (LC/MS/MS). On the day of blood collection, a 24-h dietary recall and weekly morbidity questionnaires will be used. Investigators will also use PENTA vaccines as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)). This vaccination is beneficial to the infants since the World Health Organization recommends a booster vaccination dose. At the end of the study, PENTA vaccines will also be provided to the study infants in the "no-vaccine" group.

On day 0, all infants (n=40) will receive an oral dose of 13C10-retinyl acetate, and blood samples (5 mL) will be taken on day 4. On day 7 all infants (n=40) will also receive another oral dose of 13C4-retinyl acetate. 3-day later randomly selected 30 infants will receive PENTA vaccines (day 10), while the other 10 infants will receive no vaccines. 24 hours after vaccination a finger-prick blood sample will be obtained from the infants in the vaccinated group to measure CRP (QuikRead go, Orion, Finland). On the same day (day 11), blood samples (5 mL) will be obtained from infants who develop inflammation (CRP> 5mg/L) in the vaccine group and also from infants in the control group (day 11). Thus plasma micronutrients and vitamin A stores estimates on day 4 and day 11 will evaluate the effects of inflammation on the plasma micronutrient status indicators and total body vitamin A store. Blood microsamplers will be tested alongside venous blood collection to assess the feasibility of finger/heel prick sampling. Fecal samples, local surface water, and wastewater samples will be collected to test the prevalence of AMR resitomes in children and their environment.

Outcome measures/variables:

1. The following plasma biomarkers will be estimated before inflammation and 24 hours after inflammation

- Inflammation markers: C-reactive protein (CRP) (mg/L) and α1-acid glycoprotein (AGP) (g/L)

- Vitamin A status indicators: retinol (nmol/L), total body vitamin A stores (nmol), Retinol binding protein (RBP) (mg/L) and beta-carotene (nmol/L)

- Iron status indicators: ferritin (ug/L) and soluble transferrin receptor (mg/L)

- Folate/B12 status indicators: folate (nmol/L), methylmalonic acid (umol/L) and cobalamin (pmol/L)

- Trace element status indicators: selenium (ug/L), copper (ug/L) and thyroglobulin (ug/L).

2. The usefulness of a microsampler device to collect blood samples for future micronutrient assessments.

3. Assessment and contrast of AMR gene abundances and diversity to develop resistomes ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03801161
Study type Interventional
Source International Centre for Diarrhoeal Disease Research, Bangladesh
Contact
Status Completed
Phase N/A
Start date June 1, 2018
Completion date June 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT03679234 - Impact of Infant Formula on Caregiver-perceived Intolerance N/A
Completed NCT01681355 - Gastrointestinal Tolerance Study of a New Infant Formula N/A
Completed NCT04962594 - Safety and Efficacy of Infant Formulas Supplemented With Pre- and Probiotic(s) N/A
Completed NCT03722550 - Second Generation Human Milk Oligosaccharides Blend Study N/A
Completed NCT03703583 - Infant Feeding Practice and Gut Comfort Study
Completed NCT01515644 - Study on the Effect of Inulin in Infant Formula on Gut Health Phase 3
Completed NCT03014115 - Effects of Different ARA Formulations of Infant Formula on Fatty Acid Status, Immune Markers and Infection Rates in Infants N/A
Recruiting NCT06053112 - The Trial of a New Infant Formula in Healthy Term Chinese Infants N/A
Completed NCT03000543 - Novel Isotope Dilution Technique to Assess Vitamin A Status N/A
Not yet recruiting NCT06361719 - Efficacy of Two HMOs in Chinese Infants N/A
Terminated NCT03976596 - Measurement of in Vivo Mitochondrial Capacity in Infants
Recruiting NCT01601197 - A Study of Two Injection Techniques to Reduce Pain in Infants Undergoing Immunization Phase 3
Completed NCT01635816 - Immunogenicity of SA 14-14-2 JE Vaccine Phase 4
Completed NCT01633216 - Poliovirus Vaccine Trial in Bangladesh Phase 4
Completed NCT00957892 - Effects of Infant Formula Composition on Infant Feeding Behaviors N/A
Active, not recruiting NCT06073652 - Starter Infant Formula With Synbiotics N/A
Completed NCT01825109 - Improving Rotavirus Vaccine Immune Response Phase 3
Withdrawn NCT01507935 - Colonisation Resistance Study Phase 2
Completed NCT01594840 - Changing Chat: Diaper Tips to Improve Language Development N/A
Not yet recruiting NCT01249911 - Lactobacillus Reuteri DSM 17938 and Prevention of Respiratory and Gastrointestinal Infections in Mexican Infants Phase 3